Strong growth in 2005 first half adjusted EPS : up 26.1% at 2.22
Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products
Ämnen: Haelso-sjukvaard
-
-
Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin
I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel
-
RESOLUTION OF UK PLAVIX® LITIGATION
Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&
-
SANOFI-AVENTIS SELLS ITS INTERESTS IN WACKER-CHEMIE
- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.
-
Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers
Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers Läs mer http://en.sanofi-aventis.com/index.asp
-
Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
Läs mer på http://en.sanofi-aventis.com/press/p_press.asp
-
Strong net sales growth in the first half of 2005
Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter.
-
TRANSFER OF COMMERCIAL RIGHTS OF PLAVIX® IN JAPAN TO SANOFI-AVENTIS
- Sanofi-aventis and Daiichi Pharmaceutical Co., Ltd. announced today the transfer of all commercial rights for Plavix® (clopidogrel) in Japan from Daiichi and a jointly held partnership to sanofi-aventis Japan. The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas
-
PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH
Understanding the Factors Which Contribute to Bone Strength Geneva, Switzerland, 28 June, 2005 The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength. The panels findings, presented at the Second Joint Meetin
-
A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show
Contact: sanofi-aventis Jean Marc Podvin +33 (0)1 53 77 42 23 Salah Mahyaoui +33 (0)1 53 77 40 31 +33 (0)6 73 68 78 88 Bristol-Myers Squibb Rob Hutchinson +1 609 252 3901 +1 609 271 2704 Recent clinical findings have demonstrated that a large majority of hypertensive patients who failed to achieve blood pressure goal on monotherapy can be helped to attain goal with the angiotensin-I
-
Lovenox® Patent Trial Update
On June 15, 2005, the U.S. District Court for the Central District of California granted the Motion for Summary Judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Groups suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of US Patent no. 5,389,618 ('618 patent") by their proposed generic versions of Lovenox®. A formal entry o
-
-
DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCAEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES
Two studies show insulin glargine control of HbA1C in poorly controlled type 2 diabetes patients, with comparable rates of hypoglycemia Data presented today at the 65th Session of the American Diabetes Association (ADA), San Diego demonstrated that people with type 2 diabetes achieved significantly better glycaemic control, and also achieve it earlier, when treated with the 24-hour basal insuli
-
U.S. FDA Licenses sanofi pasteurs ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
First and Only Booster in the U.S. for Protection against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has licensed ADACEL (Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) Vaccine for protection against tetanus, d
-
SANOFI-AVENTIS JOINS THE PARIS 2012 « CLUB DES ENTREPRISES » BACKING THE PARIS BID TO HOST THE 2012 OLYMPIC AND PARALYMPIC GAMES
Sanofi-aventis, The worlds third largest pharmaceutical group, is joining the Paris 2012 Corporate Club in support of the Paris candidature to host the 2012 Olympic and Paralympic Games. As of today, 20 major companies of international stature - Accenture, Accor, Airbus, Air France, Bouygues, Carrefour, Crédit Agricole, EDF, France Télécom, Gaz de France, Lafarge, Lagardère, LVMH, Publicis, RA
-
ANNUAL GENERAL MEETING
The Annual General Meeting of sanofi-aventis shareholders was held on May 31, 2005. The General Meeting approved the financial statements for the year ended December 31,2004. Also approved was the distribution of a net dividend of 1.20 euro per share, a 17.6% increase over the previous year. The dividend will be paid out on June 7, 2005. The General Meeting has reappointed PricewaterhouseCoope
-
World Heart Federation och sanofi-aventis förenar sina krafter för att förebygga uppkomsten av hjärtkärlsjukdomar
Paris, Frankrike & Genève, Schweiz 23 maj 2005 - World Heart Federation och sanofi-aventis tillkännagav idag att de har ingått ett treårigt partnerskapsavtal för att med förenade krafter förbättra förebyggandet och kontrollen av hjärtkärlsjukdomar. Tillkännagivandet gjordes vid World Heart Federations sjätte internationella kongress om förebyggande kardiologi (ICPC) i Brasilien, och bekräf
-
New study results further enhances the role of Eloxatin® in early and advanced stages of colon cancer
Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study f
-
Taxotere® regimen demonstrates significant survival benefit in the treatment of advanced gastric cancer
Contact : Anne Bancillon 33-6-86-31-03-89 ~ Taxotere®-Based Chemotherapy Reduces Risk of Death by 23 Percent ~ Final results from the largest international study in the reatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere® (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere®, cisplatin and 5-fluorouracil)
-
2005 first-quarter net sales growth ahead of world pharmaceutical
market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by re
Visa mer
Loading...